- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Information and Evidence for Policy > Monitoring and Evaluation
- Mots-clés > access to medicines
- Mots-clés > ATM-related practices
- Mots-clés > indicator-based approach
- Mots-clés > methodology
- Mots-clés > pharmaceutical company ranking
- Mots-clés > pharmaceutical industry
- Mots-clés > pharmaceutical industry - performance
- Mots-clés > pharmaceutical industry - role
- Mots-clés > pharmaceutical industry social responsibility
(2016; 192 pages)
The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries. It highlights best and innovative practices, and areas where progress has been made and where action is still required. It has been published every two years since 2008.
The 2016 Index used a framework of 83 metrics to measure company performances relating to 51 high-burden diseases in 107 countries. For the 2016 Index, the weight of the performance pillar was increased to 50%. The framework is reviewed every two years, with reference to the Expert Review Committee of independent experts, from, among others, the WHO, governments, patient organisations, the industry, academia and investors. This process ensures that Index metrics express what stakeholders expect from pharmaceutical companies.
The Index analyses data gathered via a detailed survey of pharmaceutical company behaviour regarding access to medicine. The period of analysis for this Index is 1 June 2014 to 31 May 2016. Once data is submitted by the companies in scope, it is verified, cross-checked and supplemented by the Foundation’s research team using public databases, sources and supporting documentation. The research team scores each company’s performance per indicator, before analysing industry progress in key areas.
The 2016 Index has a sharper focus on whether companies target their actions toward the people with the greatest need for better access to medicine. For example, in pricing, the Index examines whether companies price products fairly in the countries with the greatest need for those specific products. In R&D, it looks at whether companies are developing products that are urgently needed, yet offer little commercial incentive.